<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00458796</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000538879</org_study_id>
    <secondary_id>NCRI-BISMARK</secondary_id>
    <secondary_id>ISRCTN83586728</secondary_id>
    <secondary_id>EU-20716</secondary_id>
    <secondary_id>EUDRACT-2005-001376-12</secondary_id>
    <nct_id>NCT00458796</nct_id>
  </id_info>
  <brief_title>Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone</brief_title>
  <official_title>Cost-Effective Use of Bisphosphonates in Metastatic Bone Disease - A Comparison of Bone Marker Directed Zoledronic Acid Therapy to a Standard Schedule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Zoledronic acid may help decrease the risk of broken bones, bone pain, and other
      symptoms caused by bone metastases. It may also help patients live more comfortably.

      PURPOSE: This randomized clinical trial is studying different schedules of zoledronic acid to
      compare how well they work in treating patients with breast cancer that has spread to the
      bone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Compare the frequency and timing of serious related events (e.g., fractures,
           radiotherapy to bone, hypercalcemia of malignancy, orthopedic surgery, and spinal cord
           compression) in patients with advanced breast cancer metastatic to the bone treated with
           bone marker-directed schedule vs standard schedule zoledronic acid.

      Secondary

        -  Compare the quality of life of patients treated with these regimens.

        -  Compare the clinical burden of skeletal complications in these patients.

        -  Compare pain, performance status, and analgesic use (PPA score) in these patients.

        -  Compare the incidence of new bone metastases in these patients.

        -  Compare overall survival of these patients.

        -  Compare bisphosphonate use and expenditure on administration in these patients.

      OUTLINE: This is an open-label, randomized, controlled, parallel-group, multicenter study.
      Patients are stratified according to treatment center, gender, type of concurrent systemic
      therapy at study entry (endocrine therapy [with or without trastuzumab (Herceptin^®)] vs
      chemotherapy [with or without trastuzumab] vs trastuzumab alone vs chemotherapy and endocrine
      therapy [with or without trastuzumab] vs no systemic anticancer treatment), prior
      skeletal-related event (yes vs no), duration of bisphosphonate use for metastatic disease
      prior to study entry (4-6 months vs 6-12 months), type of metastases present at study entry
      (bone only vs bone and soft tissue vs bone and visceral metastases vs bone, soft tissue, and
      visceral metastases). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I (standard schedule): Patients receive zoledronic acid IV over 15 minutes once
           every 3-4 weeks for 24 months.

        -  Arm II (bone marker-directed schedule): Patients receive zoledronic acid IV over 15
           minutes once every 3-4, 8-9, or 15-16 weeks (based on serum N-telopeptide:creatinine
           ratio) for 24 months.

      Quality of life is assessed at baseline and at 3, 6, 9, 12, 18, and 24 months.

      After completion of study therapy, patients are followed periodically for up to 3 years.

      PROJECTED ACCRUAL: A total of 1,500 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fractures</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiotherapy to bone either for relief of pain or to treat or prevent pathological fractures or spinal cord compression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypercalcemia of malignancy</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Orthopedic surgery to prevent or treat pathological fractures or spinal cord compression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Spinal cord compression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life as measured by QLQ-C30 and the QLQ-BR23 breast-specific module</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical burden of skeletal complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain, performance status, and analgesic use</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new bone metastases</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bisphosphonate use and expenditure on administration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care utilization</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical utility of the &quot;point of care&quot; test for N-telopeptides (NTx) excretion</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hypercalcemia of Malignancy</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Musculoskeletal Complications</condition>
  <condition>Pain</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zoledronic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed primary breast cancer

               -  Advanced disease

          -  Radiographic confirmation of bone metastases (≥ 1 bone scan lesion must be confirmed
             as metastatic by plain radiographs or CT scan/MRI)

               -  Must have received zoledronic acid to treat metastatic bone disease (i.e., ≥ 4 or
                  5 zoledronic acid treatments prior to study entry for patients receiving 4- or
                  3-weekly infusions, respectively) for ≥ 4 months prior to study entry

               -  Any bisphosphonate to treat metastatic bone disease allowed provided it was not
                  given for more than 12 months prior to study entry

          -  No metabolic bone disease (e.g., Paget's disease of bone)

               -  Osteoporosis allowed

          -  No brain metastases

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  Male or female

          -  Menopausal status not specified

          -  WHO or ECOG performance status 0-2

          -  Life expectancy ≥ 6 months

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  AST and ALT ≤ 3 times upper limit of normal (ULN)

          -  Bilirubin ≤ 1.5 times ULN

          -  Creatinine clearance ≥ 30 mL/min

          -  No poor venous access

          -  No concurrent active dental problems, including infection of the teeth or jawbone
             (maxilla or mandibular)

          -  No prior or current diagnosis of osteonecrosis of the jaw

          -  No other cancer within the past 5 years except nonmelanomatous skin cancer, carcinoma
             in situ of the uterine cervix, or superficial bladder cancer treated with curative
             intent

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics

          -  No other prior bisphosphonate treatment within the past 3 weeks

          -  No treatment with systemic bone-seeking radioisotopes (e.g., strontium chloride Sr 89,
             samarium Sm 153 lexidronam pentasodium) within the past 3 months

          -  No wide-field (hemibody) radiotherapy within the past 3 months

               -  Recent standard-field, localized radiotherapy allowed

          -  No dental or jaw surgery (e.g., extractions, implants) within the past 4 weeks

          -  No other concurrent bisphosphonates

          -  No concurrent medication with drugs known to affect bone metabolism (e.g., calcitonin
             or high-dose systemic corticosteroids [&gt; 10 mg prednisolone/day or equivalent])

               -  Systemic or oral corticosteroids allowed for clearly indicated conditions (e.g.,
                  chemotherapy-induced emesis, brain metastases, compression syndromes)

          -  Concurrent chemotherapy, biological therapy, or endocrine therapy allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert E. Coleman, MD, FRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Research Centre at Weston Park Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>England</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamas Hickish, MD</last_name>
      <phone>44-1202-704-789</phone>
      <email>tamas.hickish@rbch.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Derbyshire Royal Infirmary</name>
      <address>
        <city>Derby</city>
        <state>England</state>
        <zip>DE1 2QY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Woodings, MRCP, FRCR, MBCHB</last_name>
      <phone>44-1332-347-141 ext. 4575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doncaster Royal Infirmary</name>
      <address>
        <city>Doncaster</city>
        <state>England</state>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doncaster Royal Infirmary</last_name>
      <phone>44-1302-366-666</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Durham</name>
      <address>
        <city>Durham</city>
        <state>England</state>
        <zip>DH1 5TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Taylor, MD</last_name>
      <phone>44-19-333-2659</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diana Princess of Wales Hospital</name>
      <address>
        <city>Grimsby</city>
        <state>England</state>
        <zip>DN33 2BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil Upadhyay, MD</last_name>
      <phone>44-147-287-4111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre at Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>England</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen J. Houston, MD</last_name>
      <phone>44-1483-571-122 ext. 6744</phone>
      <email>stephen.houston@royalsurrey.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huddersfield Royal Infirmary</name>
      <address>
        <city>Huddersfield, West Yorks</city>
        <state>England</state>
        <zip>HD3 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnathan Joffe, MD</last_name>
      <phone>44-1484-342-150</phone>
      <email>jk.joffe@cht.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan M. O, MD</last_name>
      <phone>44-151-334-1155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher J. Gallagher, MD</last_name>
      <phone>44-20-7601-8521</phone>
      <email>chris.gallagher@bartsandthelondon.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew M. Wardley, MD</last_name>
      <phone>44-161-446-3746</phone>
      <email>andrew.wardley@christie-tr.nwest.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Withington Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 8LR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew M. Wardley, MD</last_name>
      <phone>44-161-611-3186</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan M. O, MD</last_name>
      <phone>44-151-334-1155</phone>
      <email>sue.oreilly@ccotrust.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>George Eliot Hospital</name>
      <address>
        <city>Nuneaton</city>
        <state>England</state>
        <zip>CV10 7DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Fresco, MD</last_name>
      <phone>44-247-686-5512</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dorset Cancer Centre</name>
      <address>
        <city>Poole Dorset</city>
        <state>England</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Dean, MD</last_name>
      <phone>44-1202-442-491</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scunthorpe General Hospital</name>
      <address>
        <city>Scunthorpe</city>
        <state>England</state>
        <zip>DN15 7BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiagarajan Sreenivasant</last_name>
      <phone>44-0172-428-2282 ext. 5144</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S1O 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert E. Coleman, MD, FRCP</last_name>
      <phone>44-114-226-5213</phone>
      <email>r.e.coleman@sheffield.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Shrewsbury Hospital</name>
      <address>
        <city>Shrewsbury</city>
        <state>England</state>
        <zip>SY3 8XQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajiv K. Agrawal, MD</last_name>
      <phone>01743-261334</phone>
      <email>rajiv.agrawal@rsh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Solihull Hospital</name>
      <address>
        <city>Solihull</city>
        <state>England</state>
        <zip>B91 2JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Stockdale, MD</last_name>
      <phone>44-24-7696-7151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Simmonds</last_name>
      <phone>44-23-8079-3627</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Warwickshire Hospital</name>
      <address>
        <city>Warwick, Warwickshire</city>
        <state>England</state>
        <zip>CV34 5BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Jones, MD</last_name>
      <phone>44-24-7696-7151</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southend University Hospital NHS Foundation Trust</name>
      <address>
        <city>Westcliff-On-Sea</city>
        <state>England</state>
        <zip>SS0 0RY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Robinson, MD</last_name>
      <phone>44-1702-221-226</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hampshire County Hospital</name>
      <address>
        <city>Winchester</city>
        <state>England</state>
        <zip>SO22 5DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Hall, MD</last_name>
      <phone>44-1962-863-535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Infirmary</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Rizwanullah, MD</last_name>
      <phone>44-0141-211-2860</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Hicks, MD</last_name>
      <phone>44-169-836-6729</phone>
      <email>jonathan.hicks@northglasgow.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hairmyres Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hosney M. A. Yosef, MD</last_name>
      <phone>44-141-301-7066</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Crosshouse Hospital</name>
      <address>
        <city>Kilmarnock</city>
        <state>Scotland</state>
        <zip>KA2 OBE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Ritchie, MD</last_name>
      <phone>44-141-221-1724</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter J. Barrett Lee, MD</last_name>
      <phone>44-29-2031-6292</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Withybush General Hospital</name>
      <address>
        <city>Haverfordwest</city>
        <state>Wales</state>
        <zip>SA61 2PZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianfilippo Bertelli, MD, FRCPE</last_name>
      <phone>44-1437-764-545</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Gwent Hospital</name>
      <address>
        <city>Newport Gwent</city>
        <state>Wales</state>
        <zip>NP9 2UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Gaffney, MD</last_name>
      <phone>44-163-323-4266</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South West Wales Cancer Institute</name>
      <address>
        <city>Swansea</city>
        <state>Wales</state>
        <zip>SA2 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gianfilippo Bertelli, MD, FRCPE</last_name>
      <phone>44-179-228-5826</phone>
      <email>gianfilippo.bertelli@swansea-tr.wales.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2007</study_first_submitted>
  <study_first_submitted_qc>April 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2007</study_first_posted>
  <last_update_submitted>August 23, 2013</last_update_submitted>
  <last_update_submitted_qc>August 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <keyword>hypercalcemia of malignancy</keyword>
  <keyword>musculoskeletal complications</keyword>
  <keyword>pain</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Hypercalcemia</mesh_term>
    <mesh_term>Paraneoplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

